These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35064379)

  • 21. A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment.
    Cui Y; Leng C
    Front Cell Dev Biol; 2023; 11():1070777. PubMed ID: 36755971
    [No Abstract]   [Full Text] [Related]  

  • 22. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
    Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
    Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SENP1 knockdown potentiates the apoptosis, cell cycle arrest, and reduces cisplatin resistance of diffuse large B cell lymphoma cells via inducing ferroptosis.
    Dong J; Zheng X
    Biochem Cell Biol; 2024 Aug; 102(4):319-330. PubMed ID: 38708853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
    Liu Y; Wang J; Shen X; Li L; Zhang N; Wang X; Tang B
    Clin Exp Med; 2023 Nov; 23(7):3781-3797. PubMed ID: 37402040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma.
    Xiao W; Yu K; Deng X; Zeng Y
    Cytokine; 2024 Oct; 182():156726. PubMed ID: 39111113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
    Xiong D; Wei X; Huang W; Zheng J; Feng R
    Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
    Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
    Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
    Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
    Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
    Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma.
    Zhou F; Chen L; Lu P; Cao Y; Deng C; Liu G
    BMC Cancer; 2023 Jul; 23(1):641. PubMed ID: 37430195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma.
    Pan YB; Wang W; Cai HK; Zhang J; Teng Y; Xue J; Zhu M; Luo WD
    Front Genet; 2022; 13():911443. PubMed ID: 36035126
    [No Abstract]   [Full Text] [Related]  

  • 34. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis.
    Xu Z; Chen X; Song L; Yuan F; Yan Y
    Front Immunol; 2022; 13():834595. PubMed ID: 35281049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
    Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
    Front Immunol; 2021; 12():732006. PubMed ID: 34745101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a Ferroptosis Gene Set That Mediates the Prognosis of Squamous Cell Carcinoma of the Head and Neck.
    Li C; Wang X; Qin R; Zhong Z; Sun C
    Front Genet; 2021; 12():698040. PubMed ID: 34539737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
    Xu L; Zheng Q; Liu W
    BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis.
    Zhao M; Wang L; Wang X; He J; Yu K; Li D
    Tumori; 2024 Aug; 110(4):227-240. PubMed ID: 38183180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.